Genmab (GMAB) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Biotech company Genmab reported impressive net sales of $3,016 million for its cancer treatment DARZALEX in the third quarter of 2024, with strong performance both in the U.S. and globally. The company benefits from royalties on these sales, which are managed through a licensing agreement with Janssen Biotech.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
